Search Orphan Drug Designations and Approvals
-
| Generic Name: | autologous anti-CD19 chimeric antibody receptor T cells designed to deplete CD19+ B cells |
|---|---|
| Date Designated: | 01/31/2024 |
| Orphan Designation: | Treatment of Idiopathic Inflammatory Myopathies (IIM) |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Cabaletta Bio, Inc 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







